PTGX Maintained by Barclays -- Price Target Raised to $153

Barclays has maintained an "Overweight" rating on Protagonist Therapeutics (PTGX), increasing its price target to $153 from $151. Despite this cautious optimism from analysts, Protagonist Therapeutics is considered significantly overvalued with a GF Value of $72.54 against its current price of $144.87, and insider activity shows substantial selling. The company's GF Score of 47/100 highlights strong financial strength but weak profitability and growth, suggesting investors should proceed with caution.